Comparative Medicine Core Facility Infrastructure Improvement

比较医学核心设施基础设施改善

基本信息

  • 批准号:
    7934406
  • 负责人:
  • 金额:
    $ 191.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2013-06-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The U.S. Department of Health and Human Services report "2020: A New Vision" highlights that regenerative medicine is the vanguard of the 21st century healthcare. From bone marrow transplants five decades ago to the most recent stem cell-derived organ transplantations, the National Institutes of Health and National Academies expert analysis recognize regenerative medicine as an emerging core component of modern medical practice. The proposal addresses critical gaps and needs of the core facility operations by proposing enhancements designed to establish regenerative medicine products and services, and to align Department of Comparative Medicine resources to accelerate the convergence of discovery and translation into the medicine community of practice. The proposed enhancement of the Biosafety Level-2 facility and the supporting Stabile animal facility will facilitate a comprehensive coordination of specialized infrastructure built around several state-of-the-art technological and domain-specific scientific platforms that will transform the conglomerate of independent investigators into a high performance system. Mayo Clinic's Department of Comparative Medicine is engaged in a strategic realignment of resources necessary to support the discovery, translational and applications into the clinical practice. Quality Management Systems will be strengthened to ensure best practices and integrated workflow processes. The enhanced infrastructure, systems and processes, and scientific integration will provide high-performance execution that will contribute substantially to the Mayo Clinic Model of Care.
描述(由申请人提供):美国卫生与公众服务部报告“2020:新愿景”强调再生医学是21世纪世纪医疗保健的先锋。从50年前的骨髓移植到最近的干细胞衍生器官移植,美国国立卫生研究院和国家科学院的专家分析认为再生医学是现代医学实践的新兴核心组成部分。该提案通过提出旨在建立再生医学产品和服务的增强措施,解决了核心设施运营的关键差距和需求,并调整了比较医学系的资源,以加速发现和转化到医学实践社区的融合。拟议加强生物安全2级设施和支持性稳定动物设施将促进围绕几个最先进的技术和特定领域科学平台建立的专门基础设施的全面协调,这些平台将把独立调查人员的联合体转变为一个高性能系统。马约诊所的比较医学部正在进行必要的资源战略调整,以支持发现,转化和应用到临床实践中。将加强质量管理系统,以确保最佳做法和综合工作流程。增强的基础设施、系统和流程以及科学整合将提供高性能的执行,这将大大有助于马约诊所的护理模式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GREGORY J. GORES其他文献

Orthotopic Liver Transplantation for Preoperative Early-Stage Hepatocellular Carcinoma
  • DOI:
    10.1016/s0025-6196(12)62240-x
  • 发表时间:
    1994-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    CHEE-KIAT TAN;GREGORY J. GORES;JEFFERY L. STEERS;MICHAEL K. PORAYKO;J. EILEEN HAY;JORGE RAKELA;RUSSELL H. WIESNER;RUUD A.F. KROM
  • 通讯作者:
    RUUD A.F. KROM

GREGORY J. GORES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GREGORY J. GORES', 18)}}的其他基金

Cholestatic Liver Injury
胆汁淤积性肝损伤
  • 批准号:
    10372002
  • 财政年份:
    2020
  • 资助金额:
    $ 191.18万
  • 项目类别:
Cholestatic Liver Injury
胆汁淤积性肝损伤
  • 批准号:
    10588191
  • 财政年份:
    2020
  • 资助金额:
    $ 191.18万
  • 项目类别:
Project 2: Therapeutic Inhibition of Fibroblast Growth Factor and YAP Signaling in Cholangiocarcinoma: Preclinical Studies and Clinical Trial
项目2:胆管癌中成纤维细胞生长因子和YAP信号传导的治疗性抑制:临床前研究和临床试验
  • 批准号:
    10468830
  • 财政年份:
    2018
  • 资助金额:
    $ 191.18万
  • 项目类别:
Project 2: Therapeutic Inhibition of Fibroblast Growth Factor and YAP Signaling in Cholangiocarcinoma: Preclinical Studies and Clinical Trial
项目2:胆管癌中成纤维细胞生长因子和YAP信号传导的治疗性抑制:临床前研究和临床试验
  • 批准号:
    10006083
  • 财政年份:
    2018
  • 资助金额:
    $ 191.18万
  • 项目类别:
Project 2: Therapeutic Inhibition of Fibroblast Growth Factor and YAP Signaling in Cholangiocarcinoma: Preclinical Studies and Clinical Trial
项目2:胆管癌中成纤维细胞生长因子和YAP信号传导的治疗性抑制:临床前研究和临床试验
  • 批准号:
    10251133
  • 财政年份:
    2018
  • 资助金额:
    $ 191.18万
  • 项目类别:
Enrichment Program
强化计划
  • 批准号:
    10200781
  • 财政年份:
    2009
  • 资助金额:
    $ 191.18万
  • 项目类别:
Enrichment Program
强化计划
  • 批准号:
    10630253
  • 财政年份:
    2009
  • 资助金额:
    $ 191.18万
  • 项目类别:
Enrichment Program
强化计划
  • 批准号:
    10438739
  • 财政年份:
    2009
  • 资助金额:
    $ 191.18万
  • 项目类别:
LONG-ACTING OCTREOTIDE IN THE TREATMENT OF PATIENTS
长效奥曲肽在患者治疗中的应用
  • 批准号:
    7206098
  • 财政年份:
    2005
  • 资助金额:
    $ 191.18万
  • 项目类别:
Organelle Dysfunction and Apoptosis in Liver Epithelia
肝上皮细胞器功能障碍和细胞凋亡
  • 批准号:
    8250599
  • 财政年份:
    2003
  • 资助金额:
    $ 191.18万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 191.18万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了